Douglas Miehm
Stock Analyst at RBC Capital
(4.13)
# 1,735
Out of 5,088 analysts
419
Total ratings
52.3%
Success rate
5.8%
Average return
Main Sectors:
Stocks Rated by Douglas Miehm
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LGND Ligand Pharmaceuticals | Maintained: Buy | $345 → $357 | $317.33 | +12.50% | 22 | Oct 30, 2026 | |
| BLCO Bausch + Lomb | Rated: Buy | $21 → $23 | $20.40 | +12.75% | 40 | Oct 29, 2026 | |
| TSX: BHC Bausch Health Companies Inc. | Rated: Hold | $12.58 → $13.97 | $12.41 | +12.61% | 106 | Oct 29, 2026 | |
| TSX: WELL WELL Health Technologies Corp. | Reiterated: Buy | $7.00 | $4.20 | +66.67% | 23 | Oct 13, 2026 | |
| PCRX Pacira BioSciences | Rated: Hold | $25 → $37 | $36.39 | +0.30% | 7 | Oct 8, 2026 | |
| TSX: APTX Apotex Health Corp. | Reiterated: Buy | $43.00 | $33.67 | +27.71% | 4 | Oct 6, 2026 | |
| TSX: DHT.UN DRI Healthcare Trust | Reiterated: Buy | $21.00 → $22.00 | $18.10 | +21.55% | 43 | Sep 22, 2026 | |
| AUPH Aurinia Pharmaceuticals | Reiterated: Hold | $15 → $16 | $17.21 | -7.03% | 44 | Aug 7, 2026 | |
| TSX: DR Medical Facilities Corporation | Reiterated: Hold | $19.00 | $14.70 | +29.25% | 47 | Aug 7, 2026 | |
| TSX: GUD Knight Therapeutics Inc. | Reiterated: Buy | $9.50 → $11.00 | $11.40 | -3.51% | 28 | Aug 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $4.75 | $3.50 | +35.71% | 10 | Aug 6, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $7.82 | $13.99 | -44.08% | 1 | Mar 19, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $2.5 → $3.5 | $0.4277 | +718.33% | 30 | Nov 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $18 → $19 | $2.64 | n/a | 2 | Oct 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | €22.00 | €81.10 | n/a | 3 | Jun 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Hold | $1 | $7.19 | n/a | 6 | Aug 4, 2016 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | $3 → $2.3 | $0.000001 | n/a | 2 | Nov 6, 2013 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgraded: Buy | n/a | $9.00 | n/a | 1 | Feb 5, 2009 |
Ligand Pharmaceuticals
Oct 30, 2026
Maintained: Buy
Price Target: $345 → $357
Current: $317.33
Upside: +12.50%
Bausch + Lomb
Oct 29, 2026
Rated: Buy
Price Target: $21 → $23
Current: $20.40
Upside: +12.75%
Bausch Health Companies Inc.
Oct 29, 2026
Rated: Hold
Price Target: $12.58 → $13.97
Current: $12.41
Upside: +12.61%
WELL Health Technologies Corp.
Oct 13, 2026
Reiterated: Buy
Price Target: $7.00
Current: $4.20
Upside: +66.67%
Pacira BioSciences
Oct 8, 2026
Rated: Hold
Price Target: $25 → $37
Current: $36.39
Upside: +0.30%
Apotex Health Corp.
Oct 6, 2026
Reiterated: Buy
Price Target: $43.00
Current: $33.67
Upside: +27.71%
DRI Healthcare Trust
Sep 22, 2026
Reiterated: Buy
Price Target: $21.00 → $22.00
Current: $18.10
Upside: +21.55%
Aurinia Pharmaceuticals
Aug 7, 2026
Reiterated: Hold
Price Target: $15 → $16
Current: $17.21
Upside: -7.03%
Medical Facilities Corporation
Aug 7, 2026
Reiterated: Hold
Price Target: $19.00
Current: $14.70
Upside: +29.25%
Knight Therapeutics Inc.
Aug 7, 2026
Reiterated: Buy
Price Target: $9.50 → $11.00
Current: $11.40
Upside: -3.51%
Aug 6, 2026
Reiterated: Hold
Price Target: $4.75
Current: $3.50
Upside: +35.71%
Mar 19, 2026
Reiterated: Buy
Price Target: $7.82
Current: $13.99
Upside: -44.08%
Nov 19, 2025
Reiterated: Buy
Price Target: $2.5 → $3.5
Current: $0.4277
Upside: +718.33%
Oct 8, 2021
Reiterated: Hold
Price Target: $18 → $19
Current: $2.64
Upside: n/a
Jun 23, 2021
Reiterated: Buy
Price Target: €22.00
Current: €81.10
Upside: n/a
Aug 4, 2016
Reiterated: Hold
Price Target: $1
Current: $7.19
Upside: n/a
Nov 6, 2013
Rated: Hold
Price Target: $3 → $2.3
Current: $0.000001
Upside: n/a
Feb 5, 2009
Upgraded: Buy
Price Target: n/a
Current: $9.00
Upside: n/a